The Cancer Genomics Consortium (CGC) was formed in August, 2009 by a group of clinical cytogeneticists, molecular geneticists, and molecular pathologists, who are interested in applying microarray technologies to cancer diagnosis and cancer research .

The mission of the consortium is to promote communication and collaboration among cancer cytogenomics laboratories. Our goals are to (1) establish platform-neutral and cancer specific microarray designs for diagnostic purposes, (2) share cancer microarray data between participating institutions for education purposes, (3) create a public cancer array database, and (4) carry out multicenter cancer genome translational research. Collaboration amongst the different laboratories and researchers will not only provide validation for the microarray design(s) but ultimately provide more comprehensive molecular information and more accurate interpretation to better serve cancer patients and further cancer research. The CGC was officially incorporated in June 2010 as a not-for-profit organization. The members of the CGC elected the first CGC board including the president, president-elect, secretary, treasurer, and board of directors in November 2010.

Since its institution, the CGC has become the major driving force in the emerging field of cancer cytogenomics.  The CGC has designed two versions of cancer specific microarray designs which are now adopted by many microarray manufacturers. The CGC has also conducted a multicenter, cross-platform cytogenomic microarray study and has presented the preliminary results at the AMP meeting in 2011, and will present the data at the ACMG meeting and the ACC meeting.  The CGC has successfully organized four annual meetings and will hold its fifth meeting in August 2014. The CGC partnered with the Amercian College of Medical Gentetics (ACMG) and produced the first draft of technical standards and guidelines for microarray analysis of genomic abnormalities in neoplastic disorders. Other ongoing projects conducted by the CGC include creating a database for copy number variations in cancer and addressing genomic study-associated legal, ethical, and social issues.

Today, the CGC has grown to include more than 300 members from over 150 organizations in the U.S., Canada, and abroad. We encourage all members to actively participate in the CGC activities and welcome members’ comments and suggestions. Working together, we are confident that we will be able to reach our goals, fostering new cancer genetic discoveries and bringing exciting new technologies to cancer patients.

Comments are closed.